IMPEDIMED TECHNOLOGY BACKED BY NEW STUDY

Written on the 14 September 2016 by James Perkins

IMPEDIMED TECHNOLOGY BACKED BY NEW STUDY A STUDY has found that Brisbane-based company ImpediMed's (ASX: IPD) L-Dex technology (pictured) is effective in monitoring patients that are at-risk of breast cancer related lymphoedema.

The study, conducted in the United States and published in the journal Frontiers in Oncology, reported that 326 patients were monitored with the L-Dex technology  post axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB).

Through monitoring fluid status and body composition through bioimpedance spectroscopy, L-Dex allowed for early intervention for patients who showed further incidence of sub-clinical lymphoedema after undergoing either an ALND or SLNB and allowed reduction in the persistence of this condition by 99.5 per cent for ALND patients and 91.4 per cent for SLNB patients.

The study concluded, "The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up."

The researchers, from Texas, noted that this was critically important, given new health guidelines in the US for monitoring the post-treatment follow-up care of for breast cancer patients.

"As we await the results of the post-approval L-Dex study currently underway, we are pleased at the publication of these important and positive clinical data for L-Dex," says Richard Carreon, ImpediMed Managing Director and CEO in a statement to the ASX today.

L-Dex was developed by Associate Professor Leigh Ward from the University of Queensland.

IPD is trading up 6.55 per cent on the ASX this morning, at $3.94 per share.



Author: James Perkins Connect via: Twitter LinkedIn

Latest News

THE COMPANY THAT DECIDED IT WAS GOING TO GIVE A CRAP THANKS TO CROWD FUNDING

SIMON Griffiths is using toilet paper to save the world.

In 2012, on the back of an IndieGoGo crowdfunding campaig...

TECHNOLOGYONE OUTSTRIPS PROFIT EXPECTATIONS AS R&D SKYROCKETS

TECHNOLOGYONE (ASX: TNE) has surpassed market expectations to achieve a half-year profit after tax of $8.1 million, u...

CLASS ACTION FILED AGAINST SURFSTITCH AFTER ANOTHER EARNINGS WIPEOUT

AS ONLINE retailer SurfStitch (ASX: SRF) battles for survival following another negative earnings forecast, a $100 mi...

SURFSTITCH DOWNGRADES EARNINGS AS SHARES PLUNGE 25 PER CENT IN A DAY

TROUBLED online sports clothing retailer SurfStitch is considering selling off more of its assets and will close i...

Related News

THE COMPANY THAT DECIDED IT WAS GOING TO GIVE A CRAP THANKS TO CROWD FUNDING

SIMON Griffiths is using toilet paper to save the world.

In 2012, on the back of an IndieGoGo crowdfunding campaig...

SURFSTITCH DOWNGRADES EARNINGS AS SHARES PLUNGE 25 PER CENT IN A DAY

TROUBLED online sports clothing retailer SurfStitch is considering selling off more of its assets and will close i...

AUSCANN RESUMES TRADE AFTER $12 MILLION CAPITAL RAISING

IT'S BEEN a big few days for medical cannabis manufacturer AusCann (ASX: AC8), as the company emerged from a trad...

APN AND oOh!media MERGER CALLED OFF, CEO 'AMAZED' AT ACCC'S DECISION

THE PROPOSED $1.6 billion merger between Australia's two largest advertising groups, APN (ASX: APO) and oOh!me...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter